Search

Your search keyword '"DE AMICI, M"' showing total 648 results
Start Over Author "DE AMICI, M"
648 results on '"DE AMICI, M"'

1. Biological Therapies in Children and Adolescents with Severe Uncontrolled Asthma: A Practical Review

Author

Votto M, De Filippo M, Licari A, Marseglia A, De Amici M, and Marseglia GL

Subjects
severe asthma, children, adolescents, biological therapy, endotype, phenotype., Medicine (General), R5-920
Abstract

Martina Votto,1,2,* Maria De Filippo,1,2,* Amelia Licari,1,2 Alessia Marseglia,2 Mara De Amici,3 Gian Luigi Marseglia1,2 1Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 2Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; 3Immuno-Allergology Laboratory, Clinical Chemistry Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy*These authors contributed equally to this workCorrespondence: Amelia LicariPediatric Clinic, Fondazione IRCCS Policlinico San Matteo, p.le C. Golgi n.19, Pavia, 27100, ItalyTel/Fax +390382502629Email amelia.licari@unipv.itAbstract: Severe uncontrolled asthma is a complex and heterogeneous disease. A multidisciplinary assessment is required to correctly identify and manage children and adolescents with severe asthma because they may require strict monitoring and additional treatment with advanced targeted therapies. Recent research efforts have focused on identifying epidemiologic, clinical, and molecular mechanisms that underlie severe asthma, leading to the recognition of different phenotypes and endotypes and identifying biomarkers able to predict the response to biologic therapies. Additional progress has occurred by introducing biological therapies that have revolutionized the care of chronic allergic diseases in the adult and pediatric population. In this review, we briefly summarized the current literature on biological therapies to treat severe asthma in children and adolescents.Keywords: severe asthma, children, adolescents, biological therapy, endotype, phenotype

Published
2021

6. ICH3, a selective alpha7 nicotinic acetylcholine receptor agonist, modulates adipocyte inflammation associated with obesity

Author

Scabia, G., Cancello, R., Dallanoce, C., Berger, S., Matera, C., Dattilo, A., Zulian, A., Barone, I., Ceccarini, G., Santini, F., De Amici, M., Di Blasio, A. M., and Maffei, M.

Abstract

Purpose: The alpha7 nicotinic acetylcholine receptor (α7nAChR), involved in the modulation of inflammation and insulin sensitivity, is downregulated in white adipose tissue (WAT) of obese patients. This study aims to test the ability of a selective synthetic α7nAChR agonist, the spirocyclic Δ2-isoxazoline derivative (R)-(−)-ICH3 (ICH3), to counteract acute inflammation and obesity-associated modifications in WAT. Methods: We employed the LPS-septic shock murine model, human primary adipocytes and diet-induced obese (DIO) mice. Inflammatory factor expression was assessed by ELISA and quantitative real-time PCR. Flow cytometry was employed to define WAT inflammatory infiltrate. Insulin signaling was monitored by quantification of AKT phosphorylation. Results: In the septic shock model, ICH3 revealed antipyretic action and reduced the surge of circulating cytokines. In vitro, ICH3 stimulation (10 µM) preserved viability of human adipocytes, decreased IL-6 mRNA (P< 0.05) and blunted LPS-induced peak of TNFα (P< 0.05) and IL-6 (P< 0.01). Chronic administration of ICH3 to DIO mice was associated with lower numbers of CD8+ T cells (P< 0.05) and to changed WAT expression of inflammatory factors (Hp, P< 0.05; CD301/MGL1, P< 0.01; Arg-1, P< 0.05). As compared to untreated, ICH3 DIO mice exhibited improved insulin signaling in the skeletal muscle (P< 0.01) mirrored by an improved response to glucose load (ipGTT: P< 0.05 at 120 min). Conclusions: We proved that ICH3 is an anti-inflammatory drug, able to reduce inflammatory cytokines in human adipocytes and to blunt the effects of obesity on WAT inflammatory profile, on glucose tolerance and on tissue insulin sensitivity.

Published
2024
Full Text
View/download PDF

15. Spezifisches IgE gegen Staphylococcus-aureus-Superantigene bei Patienten mit bullosem Pemphigoid

Author

Michelerio, A, Carugno, A, Barruscotti, S, De Silvestri, A, De Amici, M, Tomasini, C, Vassallo, C, Michelerio, Andrea, Carugno, Andrea, Barruscotti, Stefania, De Silvestri, Annalisa, De Amici, Mara, Tomasini, Carlo, Vassallo, Camilla, Michelerio, A, Carugno, A, Barruscotti, S, De Silvestri, A, De Amici, M, Tomasini, C, Vassallo, C, Michelerio, Andrea, Carugno, Andrea, Barruscotti, Stefania, De Silvestri, Annalisa, De Amici, Mara, Tomasini, Carlo, and Vassallo, Camilla

Published
2021

16. Specific IgE to Staphylococcus aureus superantigens in patients affected by bullous pemphigoid

Author

Michelerio, A, Carugno, A, Barruscotti, S, De Silvestri, A, De Amici, M, Tomasini, C, Vassallo, C, Michelerio, Andrea, Carugno, Andrea, Barruscotti, Stefania, De Silvestri, Annalisa, De Amici, Mara, Tomasini, Carlo, Vassallo, Camilla, Michelerio, A, Carugno, A, Barruscotti, S, De Silvestri, A, De Amici, M, Tomasini, C, Vassallo, C, Michelerio, Andrea, Carugno, Andrea, Barruscotti, Stefania, De Silvestri, Annalisa, De Amici, Mara, Tomasini, Carlo, and Vassallo, Camilla

Published
2021

26. CD23 during SIT

Author

Alesina, R., De Amici, M., Quaglini, S., Puggioni, F., and Moratti, R.

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results